HC Wainwright Begins Coverage on Sarepta Therapeutics (SRPT)

HC Wainwright assumed coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $75.00 price target on the biotechnology company’s stock.

SRPT has been the topic of several other research reports. BidaskClub cut Sarepta Therapeutics from a buy rating to a hold rating in a report on Friday, August 4th. Nomura restated a buy rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Robert W. Baird restated an outperform rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Needham & Company LLC restated a buy rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Finally, Barclays started coverage on Sarepta Therapeutics in a report on Wednesday, September 6th. They set an equal weight rating and a $46.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $64.14.

Sarepta Therapeutics (NASDAQ:SRPT) opened at $54.29 on Friday. The company has a quick ratio of 9.52, a current ratio of 10.44 and a debt-to-equity ratio of 0.04. Sarepta Therapeutics has a 1 year low of $26.26 and a 1 year high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.66. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same quarter last year, the business posted ($0.95) earnings per share. analysts predict that Sarepta Therapeutics will post -3.11 earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total transaction of $575,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now owns 13,333 shares in the company, valued at approximately $745,181.37. The disclosure for this sale can be found here. Insiders sold 28,167 shares of company stock worth $1,497,619 in the last quarter. 9.60% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of SRPT. Jennison Associates LLC lifted its stake in shares of Sarepta Therapeutics by 103.9% during the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Sarepta Therapeutics during the third quarter worth about $26,011,000. Voya Investment Management LLC lifted its stake in shares of Sarepta Therapeutics by 2,786.1% during the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares in the last quarter. Gilder Gagnon Howe & Co. LLC lifted its stake in shares of Sarepta Therapeutics by 3,599.4% during the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after purchasing an additional 519,650 shares in the last quarter. Finally, HealthCor Management L.P. lifted its stake in shares of Sarepta Therapeutics by 31.1% during the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares in the last quarter. Institutional investors own 82.02% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.chaffeybreeze.com/2017/12/05/hc-wainwright-begins-coverage-on-sarepta-therapeutics-srpt.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply